Seres Therapeutics shares are trading higher after the company announced preliminary key VOWST launch metrics and FDA Fast Track Designation for SER-155.
Portfolio Pulse from Benzinga Newsdesk
Seres Therapeutics' stock is up following the announcement of preliminary VOWST launch metrics and FDA Fast Track Designation for its SER-155 treatment.
January 09, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seres Therapeutics' shares rose after announcing preliminary VOWST launch metrics and receiving FDA Fast Track Designation for SER-155.
The positive market reaction is likely due to the FDA Fast Track Designation, which can expedite the review process of SER-155, potentially leading to quicker market access and revenue generation. Preliminary VOWST launch metrics may also suggest a strong market interest or uptake for the treatment, further bolstering investor confidence.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100